Joseph Bovi, MD

Publications

• Prevention of Brain Metastases.

  (Bovi JA.) Front Neurol. 2018;9:758.

• Consolidative Whole-Brain Radiation Therapy Versus Autologous Stem Cell Transplant for Primary Central Nervous System Lymphoma: A Large Dose of Perspective and Perhaps a Lower Dose of Radiation Are in Order.

  (Bovi JA, Schultz CJ, Mehta MP, Corn BW.) Int J Radiat Oncol Biol Phys. 2018 Sep 01;102(1):59-60.

• Current Predictive Indices and Nomograms To Enable Personalization of Radiation Therapy for Patients With Secondary Malignant Neoplasms of the Central Nervous System: A Review.

  (Gilbride L, Siker M, Bovi J, Gore E, Schultz C, Hall WA.) Neurosurgery. 2018 May 01;82(5):595-603.

• Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539.

  (Rogers L, Zhang P, Vogelbaum MA, Perry A, Ashby LS, Modi JM, Alleman AM, Galvin J, Brachman D, Jenrette JM, De Groot J, Bovi JA, Werner-Wasik M, Knisely JPS, Mehta MP.) J Neurosurg. 2018 Jul;129(1):35-47.

• Clinical Significance of Updated MRI Simulation Versus Immediate Postoperative MRI for Radiation Treatment Planning in Patients With Glioblastoma: Changes in FLAIR Signal.

  (Dayal A, Siker ML, Firat S, Bovi JA, Schultz CJ, Mueller WM, Connelly JM, Rand SD.) Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):E103.

• Dosimetric Feasibility of Preoperative Partial Breast Irradiation in Prone Position Using a Magnetic Resonance Linear Accelerator.

  (Prior PW Jr, Currey AD, Kelly TR, Bovi JA, Bergom C, Li A.) Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):E691-E692.

• Pulsed Reduced Dose Rate Reirradiation (PRDR) Using Modulated Arc (mARC) Intensity Modulated Radiation Therapy for Recurrent Gliomas: Initial Clinical Outcomes of a Novel Technique.

  (Siker ML, Firat S, Prah D, Schultz CJ, Dayal A, Masterson C, Connelly JM, Mueller WM, Bovi JA.) Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):E125-E126.

• Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma.

  (Nguyen HS, Milbach N, Hurrell SL, Cochran E, Connelly J, Bovi JA, Schultz CJ, Mueller WM, Rand SD, Schmainda KM, LaViolette PS.) AJNR Am J Neuroradiol. 2016 12;37(12):2201-2208.

• Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227.

  (Glass J, Won M, Schultz CJ, Brat D, Bartlett NL, Suh JH, Werner-Wasik M, Fisher BJ, Liepman MK, Augspurger M, Bokstein F, Bovi JA, Solhjem MC, Mehta MP.) J Clin Oncol. 2016 05 10;34(14):1620-5.

• Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539.

  (Rogers CL, Perry A, Pugh S, Vogelbaum MA, Brachman D, McMillan W, Jenrette J, Barani I, Shrieve D, Sloan A, Bovi J, Kwok Y, Burri SH, Chao ST, Spalding AC, Anscher MS, Bloom B, Mehta M.) Neuro Oncol. 2016 Apr;18(4):565-74.

• Evaluation of pre-radiotherapy apparent diffusion coefficient (ADC): patterns of recurrence and survival outcomes analysis in patients treated for glioblastoma multiforme.

  (Elson A, Paulson E, Bovi J, Siker M, Schultz C, Laviolette PS.) J Neurooncol. 2015 May;123(1):179-88.

• Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.

  (Brachman DG, Pugh SL, Ashby LS, Thomas TA, Dunbar EM, Narayan S, Robins HI, Bovi JA, Rockhill JK, Won M, Curran WP.) Int J Radiat Oncol Biol Phys. 2015 Apr 01;91(5):961-7.